<?xml version="1.0" encoding="UTF-8"?>
<ReportSnapshot Major="1" Minor="0" Revision="1">
	<CoIDs>
		<CoID Type="RepNo">AC445</CoID>
		<CoID Type="CompanyName">Achillion Pharmaceuticals, Inc.</CoID>
		<CoID Type="IRSNo">522113479</CoID>
		<CoID Type="CIKNo">0001070336</CoID>
	</CoIDs>
	<Issues>
		<Issue ID="1" Type="C" Desc="Common Stock" Order="1">
			<IssueID Type="Name">Ordinary Shares</IssueID>
			<IssueID Type="Ticker">ACHN</IssueID>
			<IssueID Type="CUSIP">00448Q201</IssueID>
			<IssueID Type="ISIN">US00448Q2012</IssueID>
			<IssueID Type="RIC">ACHN.O</IssueID>
			<IssueID Type="SEDOL">B17T9T8</IssueID>
			<IssueID Type="DisplayRIC">ACHN.OQ</IssueID>
			<IssueID Type="InstrumentPI">25521168</IssueID>
			<IssueID Type="QuotePI">28645837</IssueID>
			<Exchange Code="NASD" Country="USA">NASDAQ</Exchange>
		</Issue>
	</Issues>
	<CoGeneralInfo>
		<CoStatus Code="1">Active</CoStatus>
		<CoType Code="EQU">Equity Issue</CoType>
		<LastModified>2017-08-16</LastModified>
		<LatestAvailableAnnual>2016-12-31</LatestAvailableAnnual>
		<LatestAvailableInterim>2017-06-30</LatestAvailableInterim>
		<Employees LastUpdated="2017-02-20">81</Employees>
		<SharesOut Date="2017-08-01" TotalFloat="136606872.0">136761605.0</SharesOut>
		<CommonShareholders Date="2016-12-31">68</CommonShareholders>
		<ReportingCurrency Code="USD">U.S. Dollars</ReportingCurrency>
		<MostRecentExchange Date="2017-08-22">1.0</MostRecentExchange>
	</CoGeneralInfo>
	<TextInfo>
		<Text Type="Business Summary" lastModified="2017-04-04T00:33:30">Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.</Text>
		<Text Type="Financial Summary" lastModified="2017-08-16T05:26:52">BRIEF: For the six months ended 30 June 2017, Achillion Pharmaceuticals, Inc. revenues was not reported. Net loss increased 17% to $42.7M. Higher net loss reflects Outsourced research and supplies increase of 33% to $17.7M (expense), Professional and consulting fees increase of 67% to $2.8M (expense), Professional and consulting fees increase of 35% to $2.8M (expense).</Text>
	</TextInfo>
	<contactInfo lastUpdated="2017-08-16T05:27:23">
		<streetAddress line="1">300 George St</streetAddress>
		<streetAddress line="2"></streetAddress>
		<streetAddress line="3"></streetAddress>
		<city>NEW HAVEN</city>
		<state-region>CT</state-region>
		<postalCode>06511-6624</postalCode>
		<country code="USA">United States</country>
		<contactName></contactName>
		<contactTitle></contactTitle>
		<phone>
			<phone type="mainphone">
				<countryPhoneCode>1</countryPhoneCode>
				<city-areacode>203</city-areacode>
				<number>6247000</number>
			</phone>
			<phone type="mainfax">
				<countryPhoneCode>1</countryPhoneCode>
				<city-areacode>203</city-areacode>
				<number>6247003</number>
			</phone>
		</phone>
	</contactInfo>
	<webLinks lastUpdated="2016-05-27T11:30:27"><webSite mainCategory="Home Page">http://www.achillion.com/</webSite><eMail mainCategory="Company Contact/E-mail">mfenton@achillion.com</eMail></webLinks>
	<peerInfo lastUpdated="2017-08-16T05:27:23">
		<IndustryInfo>
			<Industry type="TRBC" order="1" reported="0" code="5620201011" mnem="">Bio Therapeutic Drugs</Industry>
			<Industry type="NAICS" order="1" reported="0" code="325412" mnem="">Pharmaceutical Preparation  Manufacturing</Industry>
			<Industry type="NAICS" order="2" reported="0" code="54171" mnem="">Research and Development in the Physical, Engineering, and Life Sciences</Industry>
			<Industry type="SIC" order="0" reported="1" code="2834" mnem="">Pharmaceutical Preparations</Industry>
			<Industry type="SIC" order="1" reported="0" code="2834" mnem="">Pharmaceutical Preparations</Industry>
			<Industry type="SIC" order="2" reported="0" code="8731" mnem="">Commercial Physical Research</Industry>
		</IndustryInfo>
	</peerInfo>
	<officers>
		<officer rank="1" since="03/09/2010">
			<firstName>David</firstName>
			<mI>I.</mI>
			<lastName>Scheer</lastName>
			<age>63 </age>
			<title startYear="2010" startMonth="03" startDay="09" iD1="CHM" abbr1="Chmn." iD2="DRC" abbr2="Dir.">Chairman of the Board</title>
		</officer>
		<officer rank="2" since="09/2001">
			<firstName>Milind</firstName>
			<mI>S.</mI>
			<lastName>Deshpande</lastName>
			<age>59 </age>
			<title startYear="2013" startMonth="05" startDay="" iD1="PRE" abbr1="Pres." iD2="CEO" abbr2="CEO">President, Chief Executive Officer, Director</title>
		</officer>
		<officer rank="3" since="10/2000">
			<firstName>Mary</firstName>
			<mI>Kay</mI>
			<lastName>Fenton</lastName>
			<age>51 </age>
			<title startYear="2015" startMonth="" startDay="" iD1="CFO" abbr1="CFO" iD2="EVP" abbr2="Exec. VP">Chief Financial Officer, Executive Vice President</title>
		</officer>
		<officer rank="4" since="02/01/2016">
			<firstName>Martha</firstName>
			<mI>E.</mI>
			<lastName>Manning</lastName>
			<age>61 </age>
			<title startYear="2016" startMonth="02" startDay="01" iD1="EVP" abbr1="Exec. VP" iD2="GCN" abbr2="Counsel">Executive Vice President, General Counsel, Corporate Secretary</title>
		</officer>
		<officer rank="5" since="05/28/2013">
			<firstName>David</firstName>
			<mI></mI>
			<lastName>Apelian</lastName>
			<age>51 </age>
			<title startYear="2013" startMonth="05" startDay="28" iD1="EVP" abbr1="Exec. VP" iD2="" abbr2="">Executive Vice President, Chief Medical Officer</title>
		</officer>
		<officer rank="6" since="01/2009">
			<firstName>Joseph</firstName>
			<mI></mI>
			<lastName>Truitt</lastName>
			<age>51 </age>
			<title startYear="2014" startMonth="12" startDay="" iD1="EVP" abbr1="Exec. VP" iD2="" abbr2="">Executive Vice President, Chief Commercial Officer</title>
		</officer>
		<officer rank="7" since="02/01/2016">
			<firstName>Amy</firstName>
			<mI></mI>
			<lastName>Jennings</lastName>
			<age></age>
			<title startYear="2016" startMonth="02" startDay="01" iD1="SVP" abbr1="Sr. VP" iD2="" abbr2="">Senior Vice President - Regulatory Affairs</title>
		</officer>
	</officers>
	<Ratios PriceCurrency="USD" ReportingCurrency="USD" ExchangeRate="1.00000" LatestAvailableDate="2017-06-30">
		<Group ID="Price and Volume">
			<Ratio FieldName="NPRICE" Type="N">4.82000</Ratio>
			<Ratio FieldName="NHIG" Type="N">9.49500</Ratio>
			<Ratio FieldName="NLOW" Type="N">3.15000</Ratio>
			<Ratio FieldName="PDATE" Type="D">2017-08-23T00:00:00</Ratio>
			<Ratio FieldName="VOL10DAVG" Type="N">1.78705</Ratio>
			<Ratio FieldName="EV" Type="N">309.20190</Ratio>
		</Group>
		<Group ID="Income Statement">
			<Ratio FieldName="MKTCAP" Type="N">659.19090</Ratio>
			<Ratio FieldName="TTMREV" Type="N">15.00000</Ratio>
			<Ratio FieldName="TTMEBITD" Type="N">-70.50900</Ratio>
			<Ratio FieldName="TTMNIAC" Type="N">-67.85400</Ratio>
		</Group>
		<Group ID="Per share data">
			<Ratio FieldName="TTMEPSXCLX" Type="N">-0.49632</Ratio>
			<Ratio FieldName="TTMREVPS" Type="N">0.10972</Ratio>
			<Ratio FieldName="QBVPS" Type="N">2.65115</Ratio>
			<Ratio FieldName="QCSHPS" Type="N">2.56252</Ratio>
			<Ratio FieldName="TTMCFSHR" Type="N">-0.48835</Ratio>
			<Ratio FieldName="TTMDIVSHR" Type="N">0.00000</Ratio>
		</Group>
		<Group ID="Other Ratios">
			<Ratio FieldName="TTMGROSMGN" Type="N">-99999.99000</Ratio>
			<Ratio FieldName="TTMROEPCT" Type="N">-17.35772</Ratio>
			<Ratio FieldName="TTMPR2REV" Type="N">43.94606</Ratio>
			<Ratio FieldName="PEEXCLXOR" Type="N">-99999.99000</Ratio>
			<Ratio FieldName="PRICE2BK" Type="N">1.81808</Ratio>
			<Ratio FieldName="Employees" Type="N">81</Ratio>
		</Group>
	</Ratios>
	<ForecastData ConsensusType="Mean" CurFiscalYear="2017" CurFiscalYearEndMonth="12" CurInterimEndCalYear="2017" CurInterimEndMonth="9" EarningsBasis="PRX">
		<Ratio FieldName="ConsRecom" Type="N">
			<Value PeriodType="CURR">2.1111</Value>
		</Ratio>
		<Ratio FieldName="TargetPrice" Type="N">
			<Value PeriodType="CURR">7.12500</Value>
		</Ratio>
		<Ratio FieldName="ProjLTGrowthRate" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjPE" Type="N">
			<Value PeriodType="CURR">-7.63504</Value>
		</Ratio>
		<Ratio FieldName="ProjSales" Type="N">
			<Value PeriodType="CURR">2.25000</Value>
		</Ratio>
		<Ratio FieldName="ProjSalesQ" Type="N">
			<Value PeriodType="CURR">0.00000</Value>
		</Ratio>
		<Ratio FieldName="ProjEPS" Type="N">
			<Value PeriodType="CURR">-0.63130</Value>
		</Ratio>
		<Ratio FieldName="ProjEPSQ" Type="N">
			<Value PeriodType="CURR">-0.17290</Value>
		</Ratio>
		<Ratio FieldName="ProjProfit" Type="N">
			<Value PeriodType="CURR">-87.04540</Value>
		</Ratio>
		<Ratio FieldName="ProjDPS" Type="N">
			<Value PeriodType="CURR">0.00000</Value>
		</Ratio>
	</ForecastData>
</ReportSnapshot>
